Abstract
Background Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases.
Objectives This meta-analysis seeks to evaluate the relationship between atherogenic indices and mood disorders (MDD/BD), while identifying the most effective atherogenic biomarkers for mood disorders.
Methods This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched electronic databases, including PubMed, Google Scholar, and Web of Science, for articles published up to August 1, 2024.
Results In this meta-analysis, 85 eligible studies (14 on BD and 71 on MDD) were included, covering 70,856 participants: 18,738 patients and 52,118 healthy controls. Patients with mood disorders showed significant increases (p < 0.001) in the Castelli Risk Index 2 (CRI2), Atherogenic Index of Plasma (AIP), and (triglyceride or TG + low-density lipoprotein + very low-density lipoprotein)/(high-density lipoprotein cholesterol or HDL + Apolipoprotein A or ApoA) ratio, but not CRI1 and ApoB/ApoA ratio. Significant lower HDL and lecithin: cholesterol acyltransferase activity, and higher TG levels were observed in mood disordered patients compared with controls. There were no significant differences between MDD and BD patients. Most included studies lacked the most essential information on the inclusion and exclusion of important confounders.
Conclusions AIP is the most effective atherogenicity index for mood disorders. Regular lipid profiling and metabolic syndrome screening are crucial in mood disorders. Early intervention with lipid-lowering therapies is recommended to prevent the worsening of atherogenicity and disease progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ratchadapiseksompotch Fund, Graduate Affairs, Faculty of Medicine, Chulalongkorn University (Grant number GA64/21), a grant from CU Graduate School Thesis Grant, and Chulalongkorn University Graduate Scholarship to Commemorate the 72nd Anniversary of His Majesty King Bhumibol Adulyadej to KJ, For the Thailand Science research and Innovation fund Chulalongkorn University, MDCU (RA66/016) to MM
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Emails: ket.kett{at}hotmail.com; Abbass.chem.almulla1991{at}gmail.com, thapanee.ja{at}up.ac.th, asara.vasu{at}gmail.com, Chavit.tun{at}gmail.com, psynjansem{at}docchula.com, stojanovpisevski{at}gmail.com, elizabet.dzhambazova{at}mu-plovdiv.bg
↵# Joined first author
Data Availability
The work was designed by MM and KJ. Data were collected by KJ, TJ,AV and PJ. Statistical analyses were performed by MM and AA. All authors revised and approved the final draft.
